MedPath

Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI

Phase 3
Conditions
Platlet Aggregation
Major Bleeding Outcomes
Interventions
Registration Number
NCT00889044
Lead Sponsor
Sheba Medical Center
Brief Summary

Since the absorption of clopidogrel through the gastrointestinal tract is limited, we want to examine whether adding clopidogrel by chewing will overcome the limited gastrointestinal absorption, and hence will improve the prevention of platelet aggregation.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Male and Female older than 18 years old with non-ST myocardial infarction
Exclusion Criteria
  • Current treatment with anticoagulation medication, any type of cerebro vascular event in the past, active bleeding, active peptic ulcer disease, pregnant women, any inability to sign an informed consent of participate in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
clopidogrel by chewingclopidogrel by chewing-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Platelet aggregation and bleeding events6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Sheba_medical_center

🇮🇱

Ramat-Gan, Israel

Sheba Medical Center, Cardiac Institute

🇮🇱

Tel Hashomer, Israel

© Copyright 2025. All Rights Reserved by MedPath